Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal

Acquisition Gives The Big Biotech Its First Approved Solid Tumor Drug

Executive Summary

The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.

You may also be interested in...



Gilead’s Trodelvy Outperforms Expectations In Breast Cancer, Again

The company is presenting overall survival data in HR+/HER2- breast cancer from the TROPiCS-02 at ESMO. Oncology clinical development head Bill Grossman talked with Scrip about how it differs from rival Enhertu.

Gilead Summits Takeback Of Trodelvy Rights In Deal With Everest

Deal Snapshot: Through subsidiary Immunomedics, Gilead will pay $280m up front to gain the remaining global rights to the drug, at a time when Everest’s business model has encountered some difficulties in China.

Gilead’s Trodelvy Wins In TROPiCS-02, But Commercial Headwinds Remain

Analysts said that while the Phase III survival data could lead to Trodelvy’s FDA approval, it still could face competitive headwinds from AstraZeneca/Daiichi Sankyo’s Enhertu.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel